OBJECTIVE:To investigate the clinical effects of mouse nerve growth factor for injection combined with oxiracetam in the treatment of hypertensive cerebral hemorrhage（HCH）.METHODS:Totally 92 patients with HCH admitted into Chaoyang the Second Hospital from Oct.2017 to Jan.2019 were extracted to be divided into the observation group（n = 46） and the control group（n = 46） via the random number table.The control group was treated with oxiracetam

while the observation group received mouse nerve growth factor for injection.Patients in both groups were treated for 21 d.After treatment

the clinical efficacy of two groups was evaluated.The degree of neurological impairment and activities of daily living were evaluated before and after treatment

and the levels of serum brain injury biomarkers

inflammatory factors and oxidative stress indicators were detected.Meanwhile

the adverse drug reactions was observed in two groups.RESULTS:The total effective rate of the observation group was 93.48%（43/46）

significantly higher than that of the control group 76.09%（35/46）

with statistically significant difference（P<0.05）.After treatment

the national institutes of health stroke scale（NIHSS） scores of both groups were significantly lower and Barthel Index（BI） score was significantly higher than that before treatment;after treatment

the NIHSS score of the observation group was significantly lower than that of the control group

while the BI score was significantly higher than that of the control group

with statistically significant differences（P<0.05）.After treatment

the levels of serum brain injury biomarkers [neuron specific enolase（NSE）

S100 β protein] and related inflammatory factors[interleukin（IL）-8

tumor necrosis factor（TNF）-α

hypersensitive C-reactive protein（hs-CRP） ] in both groups were significantly lower than those before treatment

the observation group was significantly lower than the control group

with statistically significant differences（P <0.05）.After treatment

the levels of serum superoxide dismutase（SOD） increased significantly in both groups

while the levels of serum malondialdehyde（MDA） and lipid peroxide（LPO） decreased significantly;the levels of serum SOD in the observation group were significantly higher than those in the control group

and the levels of serum MDA and LPO were significantly lower than those in the control group

with statistically significant differences（P < 0.05）.The incidence of adverse drug reactions in the observation group was 15.22%（7/46）

compared with 17.39%（8/46） in the control group

the difference was not statistically significant（P > 0.05）.CONCLUSIONS:Mouse nerve growth factor for injection combined with oxiracetam in the treatment of HCH may protect the brain tissues and promote the recovery of impaired neurological impairment by downregulating the expression levels of relevant inflammatory factors and correcting the pathway of oxidative stress in the body.The overall efficacy is significant

and the patient is well tolerated.